Dark Forest Capital Management LP Increases Holdings in Edwards Lifesciences Co. (NYSE:EW)

Dark Forest Capital Management LP raised its stake in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 224.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,404 shares of the medical research company's stock after purchasing an additional 7,196 shares during the quarter. Dark Forest Capital Management LP's holdings in Edwards Lifesciences were worth $770,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in EW. Harbor Capital Advisors Inc. grew its stake in shares of Edwards Lifesciences by 2.5% in the 4th quarter. Harbor Capital Advisors Inc. now owns 11,135 shares of the medical research company's stock worth $824,000 after buying an additional 273 shares during the last quarter. Nordea Investment Management AB raised its position in shares of Edwards Lifesciences by 34.6% in the 4th quarter. Nordea Investment Management AB now owns 4,057,013 shares of the medical research company's stock worth $301,355,000 after purchasing an additional 1,043,484 shares during the last quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST raised its position in shares of Edwards Lifesciences by 6.7% in the 4th quarter. WELLCOME TRUST LTD THE as trustee of the WELLCOME TRUST now owns 4,800,000 shares of the medical research company's stock worth $355,344,000 after purchasing an additional 300,000 shares during the last quarter. Sivik Global Healthcare LLC bought a new position in Edwards Lifesciences in the 4th quarter worth about $3,702,000. Finally, Avanza Fonder AB purchased a new stake in Edwards Lifesciences during the 4th quarter valued at about $4,845,000. 79.46% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Edwards Lifesciences

In other news, VP Daniel J. Lippis sold 400 shares of the firm's stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $69.48, for a total transaction of $27,792.00. Following the completion of the transaction, the vice president now owns 22,588 shares in the company, valued at $1,569,414.24. This trade represents a 1.74 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $69.81, for a total value of $663,195.00. Following the completion of the sale, the vice president now owns 47,206 shares in the company, valued at $3,295,450.86. This represents a 16.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 71,853 shares of company stock valued at $5,163,062 in the last three months. 1.29% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Truist Financial dropped their target price on shares of Edwards Lifesciences from $78.00 to $75.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Wolfe Research downgraded Edwards Lifesciences from a "hold" rating to a "strong sell" rating in a research note on Wednesday, February 12th. Royal Bank of Canada reissued an "outperform" rating and issued a $85.00 target price on shares of Edwards Lifesciences in a report on Wednesday, February 12th. Canaccord Genuity Group upped their price target on Edwards Lifesciences from $71.00 to $75.00 and gave the company a "hold" rating in a report on Friday, April 25th. Finally, Evercore ISI reduced their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating for the company in a report on Wednesday, February 12th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and eleven have given a buy rating to the stock. According to MarketBeat, Edwards Lifesciences has an average rating of "Hold" and an average target price of $79.45.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded down $0.77 during mid-day trading on Wednesday, hitting $75.51. The stock had a trading volume of 959,764 shares, compared to its average volume of 4,978,683. Edwards Lifesciences Co. has a one year low of $58.93 and a one year high of $95.25. The company has a current ratio of 3.46, a quick ratio of 2.89 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $44.39 billion, a P/E ratio of 10.82, a P/E/G ratio of 4.82 and a beta of 1.15. The firm's 50 day moving average is $70.99 and its 200 day moving average is $71.20.

Edwards Lifesciences (NYSE:EW - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, topping analysts' consensus estimates of $0.60 by $0.04. The firm had revenue of $1.41 billion during the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business's quarterly revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.66 earnings per share. On average, sell-side analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.